Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu-and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.
received much interest until the current decade and management of pruritic conditions has been hampered by our inadequate understanding of the pathophysiology of itch. Recent advances have elucidated the mediators and neuronal pathways involved in itch transmission (Fig. 1) , and it may be that this fast emerging knowledge will be translated into new therapeutics in the near future. In addition to reviewing promising new agents, this article highlights important recent findings in the pathogenesis of itch and explores how the mediators and receptors involved can serve as potential targets for the development of novel antipruritic drugs in various diseases (Tables 1 and 2 ).
Antihistamines
Histamine has been the prototypic pruritogen for decades 2 but robust evidence for its role and the efficacy of histamine H1 receptor antagonists is limited to only a few diseases (namely urticaria, mastocytosis, allergic drug reactions and insect bite reactions). The role of histamine in most forms of chronic pruritus (defined as more than 6 weeks by the International Forum for the Study of Itch) 3 is minimal and H1 antihistamines are frequently ineffective in these conditions. The recent discovery of H3 and H4 histamine receptors and their involvement in pruritus and inflammation [4] [5] [6] [7] has, however, rekindled interest in histamine. In particular, the H4 receptor, first cloned in 2000, 8 has been found to be involved in allergic inflammation and the functioning of mast cells, eosinophils, monocytes, dendritic cells and T cells. [8] [9] [10] [11] In mice, H4 histamine receptor agonists have been shown to induce pruritus that was independent of mast cells or other haematopoietic cells; this suggests that the H4 receptor-mediated itch results from a direct action on peripheral nerves. 6 The H4 receptor antagonist JNJ-7777120 (Johnson & Johnson Pharmaceutical Research & Development, New Brunswick, NJ, U.S.A.) has been demonstrated to be efficacious in models of pruritus, asthma and allergic rhinitis. [12] [13] [14] Antagonism of the H4 receptor was also able to inhibit substance P-induced pruritus, 15 which was resistant to H1 receptor antagonists. 15, 16 The effect of H4 receptor antagonism on both pruritus and Th2 cell-mediated inflammation highlights its therapeutic potential in atopic dermatitis (AD). 17 Clinical studies are currently ongoing and this novel form of antipruritic treatment is expected to be available in the near future. 18 
Protease pathway
A distinct itch transmission pathway mediated by the pruritogen cowhage has been elucidated in recent years. 19 Cowhage is a tropical plant and the spicules on its pods contain a cysteine protease, known as mucunain, which binds to protease-activated receptor (PAR)-2 and PAR-4 20 to stimulate cutaneous mechanical-sensitive C-fibres. 21 The secondary neurones of these peripheral nerves were also found to be distinct from the neuronal pathway transmitting histamine-induced itch in primates, 22 although findings of a study in mice suggested a functional overlap between these two pathways in the spinal cord. 23 The protease-PAR-2 pathway appears to be a suitable model for the study of itch in AD. Cowhage-induced itch, similar to that of AD, does not have accompanying axonal reflex flare, is associated with burning and ⁄or pricking sensations, 24 and can be induced mechanically. 19 PAR-2 receptors, which cowhage binds to, were found to be increased in AD lesions. 25 We have also recently found that cowhage induces a far more intense sensation compared with histamine and that the protease pathway is likely to be the main determinant of itch perception when both histamine and protease pathways are activated together. 26 The protease pathway therefore plays an important role in itch transmission in AD and probably also in other chronic pruritic conditions. One approach in the management of pruritus is to target the specific components in the protease pathway, which consists of PAR-2 and endogenous proteases. These endogenous proteases includes serine proteases such as mast cell tryptase 26, 27 and kallikreins, 28 and cysteine proteases such as cathepsin S. 29 In addition to pruritus, serine proteases signalling through PAR-2 have been shown to play a regulatory role in epidermal barrier function 30 and skin inflammation. 28 Serine proteases and PAR-2 may therefore be therapeutic targets in AD, which consists of all these three features, and in other conditions such as pruritus of the elderly and ichthyosis.
Nafamostat mesilate and camostat mesilate are synthesized serine protease inhibitors that inactivate tryptase and kallikrein. Nafamostat mesilate, which has been used as an anticoagulant, has also been shown to inhibit mast cell activation and the production of inflammatory cytokines. 31, 32 The successful treatment of two patients with refractory chronic urticaria with nafamostat mesilate and camostat mesilate has recently been reported. 33 Nafamostat mesilate was also found to give effective inhibition of scratching in mice, mainly via its action on tryptase. 26, 27 Another group of drugs that target the protease pathway is the tetracyclines. Tetracycline and its derivatives, doxycycline and minocycline, were found to reduce PAR-2-mediated production of interleukin (IL)-8 in keratinocytes. 34 Tetracyclines can potentially be useful in inflammatory diseases which are pruritic, such as subsets of acne vulgaris and bullous pemphigoid, by reducing both inflammation and pruritus through their antagonistic effect on PAR-2. 38 ) has been used in laboratory studies to inhibit itch signalling.
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Opioid system
It is well known that the opioid system has a role in itch processing in the central nervous system. There is growing Current understanding of the pathological mechanisms of itch and the potential targets for itch therapeutics in the periphery, spinal cord and brain. Histamine-induced itch is transmitted via histamine-sensitive and mechanically insensitive C-fibres and protease-induced itch is transmitted via PAR-2 and mechanically positive C-fibres. Free nerve endings reach the stratum granulosum. Neurogenic inflammation is mediated by the axonal reflex, releasing neuropeptides (substance P in particular), which cause vasodilation and further inflammatory changes. PAR, protease-activated receptor; Mech., mechanical; Hist., histamine; GRP, gastrin-releasing peptide; GRPR, GRP receptor; Mrgpr, Mas-related G protein-coupled receptor; TRPV, transient receptor potential vanilloid; NKR-1, neurokinin receptor-1 evidence, however, that opioid receptors and endogenous opioid agonists are also functional in the skin, and they have been found on peripheral nerve fibres, keratinocytes, melanocytes, hair follicles and immune cells. 39 It is believed that an excess of mu-opioid receptor activity in comparison with kappa-opioid receptor activity results in pruritus, 40 and stimulation of the kappa-opioid receptor was found to inhibit mu-receptor effects both centrally and peripherally. Mu-opioid receptor antagonists, such as naloxone, naltrexone and nalmefene, have been shown in controlled clinical trials to be effective in treating pruritus associated with cholestasis, atopic dermatitis and chronic urticaria. [43] [44] [45] Nalfurafine, a kappa-opioid receptor agonist, has been shown to reduce uraemic itch significantly, 46 and was approved for use for this purpose in Japan in 2009. Its efficacy in the pruritus of chronic liver disease has also been investigated in a phase II trial, 47 but the results are currently unavailable. Two other kappa-opioid receptor agonists, bremazocine and GR 89696, 48, 49 have been shown in monkey models to inhibit itch induced by intrathecal morphine. Butorphanol is both a kappa-receptor agonist and a mu-receptor antagonist; the epidural form was found to be effective in relieving pruritus associated with epidural morphine 50 and the intranasal form has been reported to be effective in patients with severe and intractable pruritus secondary to systemic and inflammatory skin diseases. 51 Nausea and analgesia withdrawal are significant problems associated with opioid antagonists, and central nervous system depression and addiction are important side-effects with opioid agonists. Peripherally acting opioid receptor agonists and antagonists, which do not cross the blood-brain barrier, are devoid of such central effects and provide an alternative to circumvent these problems.
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Subcutaneous methylnaltrexone is a peripherally active mu-opioid receptor antagonist approved in the U.S.A. for use in patients under palliative care who do not respond sufficiently to laxative therapy. The drug has also been approved for use by Health Canada and the European Medicines Agency. In a double-blind randomized controlled trial involving 10 healthy volunteers, oral methylnaltrexone at a dose of 19AE2 mg kg )1 significantly improved itch induced by intravenous morphine. 52 Methylnaltrexone has also been used by anaesthesiologists for short-term management of pruritus in patients receiving intraspinal and epidural analgesia. 53 These results support the role of peripheral opioid receptors in mediating itch, but more studies are required to evaluate the efficacy of methylnaltrexone in pruritic conditions. Alvimopan is an orally administered peripherally acting mu-opioid receptor antagonist that has been approved in the U.S.A. for acceleration of gut function after bowel resection and primary anastomosis. Its efficacy as an antipruritic agent remains to be explored. Preliminary data on peripherally acting kappa-opioid receptor agonists suggest that they may be useful in the treatment of itch. ICI 204,448 (Tocris Bioscience, Bristol, U.K.) has previously been shown to prevent chloroquineinduced itch in mice. 54 Asimadoline (EMD-61753), which is being developed for the treatment of irritable bowel syndrome, 55 has been reported to inhibit itch induced by compound 48 ⁄80 (which degranulates mast cells to release histamine) and a kappa-receptor antagonist. 56 SA14867
(Santen Pharmaceutical Co., Osaka, Japan) has been shown to inhibit itch induced by substance P and 5-hydroperoxyeicosatetraenoic acid in mice and to attenuate morphineinduced scratching in monkeys. 57 Topical preparations of opioid receptor agonist ⁄antagonist, which would be useful in localized pruritic conditions, have been developed but are currently not commercially available. Naltrexone cream 1% has been used in patients with AD in an open study in which more than 70% of the 18 subjects experienced significant reduction in pruritus. 58 Subsequently, a placebo-controlled, crossover trial involving 40 patients with AD demonstrated that the cream was effective in reducing pruritus. 58 Lim et al. 59 formulated a topical liposomal butorphanol preparation and showed that the formulation is able to release a consistent amount of butorphanol into the systemic circulation over 24 h. This formulation, however, has not been tested in humans. Further trials involving the abovementioned topical agents will be required to demonstrate their clinical utility.
Interleukin-31
IL-31 is a cytokine that has been found to play an important role in pruritus. 60 Overexpression of IL-31 in lymphocytes in mice induced scratching and dermatitis, 61 and higher levels of IL-31 have been found in the lesions of patients with AD and prurigo nodularis. 62 A common IL-31 haplotype was found to be significantly associated with the nonatopic type of eczema (defined as the absence of specific IgE against common allergens), and this suggests that altered regulation of IL-31 gene expression is a risk factor for development of the disease. 63 A genetic mutation in the IL-31 receptor has also been recently implicated in the pathogenesis of familial primary cutaneous amyloidosis, a form of localized pruritic disease. 64, 65 IL-31 is produced predominantly by Th2 lymphocytes, 61 which are the main inflammatory cells in acute AD. Th1 lymphocytes, the predominant component of the inflammatory infiltrate in chronic AD, produce lesser amounts of IL-31. 
Vanilloids
Vanilloids are endogenous and exogenous agents that possess the ability to activate transient receptor potential vanilloid (TRPV) ion channels either directly or indirectly. The best known member is TRPV1, a nonselective cation channel expressed on both sensory neurones and non-neuronal cells (such as epidermal and hair follicular keratinocytes, mast cells, dendritic cells and endothelial cells). [67] [68] [69] Activation of TRPV1 results in excitation and subsequent desensitization of C-fibres through depletion of neuropeptides, a mechanism which has been utilized to alleviate pain and itch. 70, 71 TRPV1 was also found to be required in histamine-and serotonin-induced itch, 72 and has been shown to mediate histamine-induced itch via activation of phospholipase A2 and 12-lipoxygenase. 73 Endogenous vanilloids consist of a heterogeneous group of mediators that include histamine, prostaglandins, bradykinin, eicosanoids, adenosine triphosphate and various neurotrophins. [74] [75] [76] Topical capsaicin, the active compound in chilli pepper, is an exogenous vanilloid. It has been shown to be useful in localized, chronic pruritic diseases, particularly those of neuropathic origin, such as postherpetic itch, brachioradial pruritus and notalgia paraesthetica. 77 It has also been used in pruritus associated with haemodialysis, 78 psoriasis 79 and aquagenic pruritus. 80 Capsaicin is available over the counter in concentrations of 0AE025-0AE1%, and the main problem with its use is the initial burning sensation which usually lasts several days.
Patients can be advised to apply a topical anaesthetic, such as lignocaine or eutectic mixture of local anaesthetic (EMLA), before application of capsaicin in the first 2 weeks of treatment in order to reduce the discomfort. The topical anaesthetic, in addition, serves as an antipruritic treatment in itself. Pretreatment with an anaesthetic agent has been shown to give effective reduction of burning sensation and attenuate heat hyperalgesia during capsaicin treatment. 81 A new high-potency transdermal formulation containing 8% capsaicin (Qutenza; NeurogesX, San Mateo, CA, U.S.A.; formerly NGX4010) has recently been approved in Europe and the U.S.A. for the treatment of postherpetic neuralgia. It was shown to be superior to a low-concentration formulation in the treatment of various types of neuropathic pain 82 and a single 30-or 60-min application may provide up to 3 months of localized pain relief with minimal adverse effects. Although there are no data on its efficacy in neuropathic itch, this formulation is likely to be effective in these conditions and can be helpful in more resistant cases. Tacrolimus is a calcineurin inhibitor that may inhibit pruritus through its effects on TRPV1. In addition to its antiinflammatory action, tacrolimus has been reported to have direct antipruritic effects in AD and other diseases. [83] [84] [85] It was found to induce the release of substance P from neurones, probably by favouring phosphorylation of TRPV1 and depleting phosphatidylinositol 4,5-bisphosphate, which in turn results in inactivation of calcium channels and desensitization of neurones. 86 Unlike capsaicin, it does not bind to TRPV1
directly. TRPV3 channel is another member of the TRPV family, and has a role in thermosensation 87 and hair growth. 88 A study showed that TRPV3 transgenic mice with a Gly573Ser gainof-function mutation developed allergic dermatitis and spontaneous scratching (which was unrelated to the dermatitis). 89 Like TRPV1, TRPV3 channels were found to be similarly expressed on keratinocytes and peripheral nerves. Modulation of these channels may potentially inhibit pruritus both at the epidermis (by inhibiting the production of itch mediators by keratinocytes) and in the peripheral nerves. 90 In addition, certain agents such as camphor may act on both TRPV1 and TRPV3, 91 and this creates the opportunity for using a single agent to target multiple receptors at multiple points in the itch signalling pathway.
Cannabinoids
The efficacy of cannabinoids in pruritus has been demonstrated in a few studies. Pretreatment with topical cannabinoid receptor agonists has been found to give significant reduction of histamine-induced itch and vasodilatation in healthy volunteers. 92, 93 In mice, cannabinoid receptor antagonists, such as rimonabant, have been shown to elicit a dose-dependent increase in scratching behaviour. 94 In a large industry-sponsored trial, a cream containing N-palmitoylethanolamine (PEA) was found significantly to reduce pruritus and improve disease severity in AD. 95 PEA was found to exhibit little affinity for cannabinoid receptors, but may act by enhancing the effect of anandamide, an endocannabinoid, through inhibition of the enzyme fatty acid amide hydrolase (FAAH). 96 Anandamide was found to reduce the activity of TRPV1 in primary sensory neurones, probably by reduction of protein kinase A-mediated phosphorylation of TRPV1. 97 The role of anandamide in itch has also been demonstrated in an acute allergenic murine model in which suppression of neuronal FAAH [using FAAH inhibitor URB597 (KDS-4103) (Cayman Chemical, Ann Arbor, MI, U.S.A.)] reduced scratching response. 98 Direct-acting cannabinoid agonists also exert an antipruritic effect; however, unlike FAAH inhibitors, they have prominent central side-effects such as motor suppression, dependence and psychomimesis. 98, 99 In contrast to the centrally active URB597, a peripherally restricted FAAH inhibitor has also been developed recently. This inhibitor is known as URB937 and was shown to be effective in inhibiting pain in mice. 100 Research has been ongoing to examine drugs that prevent the catabolism of endogenous cannabinoids, and enzymes such as FAAH serve as targets for the development of new therapies for itch.
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Neurotrophins
Neurotrophins are neuropeptides that regulate the growth and function of nerve cells. The prototypic neurotrophin is nerve growth factor (NGF), whose main sources are keratinocytes and mast cells. 101 NGF has been shown to result in proliferation of nerve fibres 102 and upregulation of neuropeptides such as substance P. 103 In AD lesions, higher levels of NGF have been found in keratinocytes in the epidermal basal and spinous layers, and increased density of NGF receptors, known as tropomyosin-related kinase A (TrkA), have been noted in the epidermis and upper dermis. 104 The level of NGF in the stratum corneum also correlated with the severity of itching and eruptions in AD. 105 Increased NGF and TrkA immunoreactivities have been detected in prurigo nodularis 106 and pruritic psoriatic lesions, 107 and increased fibre density have also been found in the pruritic lesions of contact dermatitis. 108 Anti-NGF strategies have been tested in the murine AD model. Anti-NGF antibodies were shown to give significant inhibition of the development and proliferation of AD lesions and to prevent proliferation of epidermal nerves. 109 TrkA inhibitors [K252a (Calbiochem, La Jolla, CA, U.S.A.) and AG879 (Alomone Labs, Jerusalem, Israel)] were also demonstrated to give significant improvement of established dermatitis and scratching behaviour, together with decreasing nerve fibre density in the epidermis. 110 Of note, anti-NGF antibodies have been used to treat pain in patients, [111] [112] [113] and tanezumab is a monoclonal antibody 114 that has been investigated for the treatment of osteoarthritis and diabetic polyneuropathy in clinical trials. 115, 116 Anti-NGF strategies therefore provide another possible avenue for the management of chronic pruritus.
Other members of the neurotrophin family include neurotrophins 3, 4 and 5 and brain-derived neurotrophic factor (BDNF). Neurotrophin 4 was found to be increased in the prurigo lesions of patients with AD, 117 and serum levels of BDNF correlated with the degree of nocturnal scratching, disease severity and quality of life in patients with AD.
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More studies will be required to clarify the roles of neutrophin 4 and BDNF in pruritus and AD.
Acetylcholine
Acetylcholine is the main neurotransmitter in the autonomic nervous system, and may have a role in mediating pruritus. Elevated expression of acetylcholine has been found in the skin of patients with AD. 119 Intradermal injection of acetylcholine induced pain but itch was produced when the injection was performed in lesional AD skin. [120] [121] [122] This phenomenon, however, may also be explained by the central sensitization to itch that occurs in chronic AD. Botulinum toxin inhibits the release of acetylcholine from presynaptic nerve terminals. It has been shown to reduce neurogenic inflammation (inflammation secondary to the release of neuropeptides from afferent neurones) induced by histamine, capsaicin and transcutaneous electrical stimulation. [123] [124] [125] [126] The usefulness of subcutaneous botulinum toxin in localized pruritus has been reported in cases of notalgia paraesthetica, lichen simplex chronicus and neuropathic itch; [127] [128] [129] however, botulinum toxin has also been reported to be inefficacious for neuropathic itch in a case series. 130 The role of acetylcholine in pruritus and the benefits of targeting its action in therapeutics remain to be evaluated.
Toll-like receptor 7
In a recent study in mice, functional toll-like receptor 7 (TLR7) was found to be expressed in C-fibre sensory neurones and was important in mediating itch induced by nonhistaminergic pruritogens. 131 Although TLR7 appears to be functionally conserved across mice and human species, studies are required to determine its role in pruritus in humans. The effectiveness of antagonizing TRL7 to inhibit itch at the cutaneous level awaits evaluation.
Gastrin-releasing peptide and its receptor
The recent discovery of a specific group of interneurones in the dorsal horn of the spinal cord of mice provides evidence for a specific itch-transmitting central pathway that is distinct from pain signalling. 132, 133 The presence of such a pathway has long been a topic of debate. Gastrin-releasing peptide (GRP), a peptide initially discovered to play several roles in the regulation of gastrointestinal physiology, binds to GRP receptor (GRPR), a G protein-coupled receptor. In the study by Sun and Chen, 132 GRP was found to be specifically expressed in a small subset of peptidergic neurones in the dorsal root ganglia and expression of GRPR was found to be restricted to lamina I of the dorsal horn of the spinal cord. Mice with mutant GRPR and mice with a GRPR antagonist injected into their spinal cerebrospinal fluid demonstrated significantly less scratching behaviour when compound 48 ⁄80, a PAR-2 agonist, and chloroquine were applied. The GRPRmutant mice, however, demonstrated normal response to pain stimuli. Provided that a similar mechanism of itch transmission is present in humans, GRP and GRPR may be central targets that can be used to inhibit itch induced by different pruritogens.
Mas-related G protein-coupled receptors
A recent study in mice revealed that Mas-related G proteincoupled receptors (Mrgprs), a family of G protein-coupled receptors expressed exclusively in peripheral sensory neurones, function as receptors in chloroquine-induced itch. 134 Although
Mrgprs do not seem to mediate histamine-induced itch, Mrgprs are activated by neuropeptides and it is possible that they may play a role in transmission of itch induced by other substances. 135 Interestingly, the peripheral sensory neurones expressing Mrgprs also expressed GRP. This gives further support to the presence of a group of peripheral C-fibres specifically transmitting itch. A molecular model for the transmission of itch induced by chloroquine and possibly other pruritogens can also be derived from this information: the pruritogen activates Mrgprs on peripheral nerves and stimulates release of GRP in the spinal cord, which in turn activates GRPR on spinal interneurones and subsequently activates the secondary itch neurones in the spinothalamic tract. Therefore, in addition to GRP and GRPR, Mrgprs provide molecular access to itchselective neurones, and may serve as a potential target in itch therapeutics.
Substance P-neurokinin receptor
Substance P is an important neuropeptide mediating itch and neurogenic inflammation. 136, 137 It is a tachykinin that binds to neurokinin receptor (NKR)-1, NKR-2 and NKR-3, 138 but has the highest affinity for NKR-1. NKR-1 is expressed in the central nervous system and the skin and NKR-1-expressing neurones in the superficial dorsal horn of the spinal cord were found to be involved in itch transmission in rats. 139 Aprepitant is a selective high-affinity NKR-1 antagonist which has been approved for the prevention of chemotherapy-induced emesis. 140 It has been reported to be effective in cases of Sézary syndrome, erythrodermic cutaneous T-cell lymphoma, metastatic sarcoma and breast carcinoma, erlotinib-induced itch, and chronic refractory pruritus from various causes. [141] [142] [143] [144] [145] The drug has generally been well tolerated, and side-effects were mild. However, it is extremely expensive and its efficacy as an antipruritic agent requires verification in randomized controlled trials. 
Lysophosphatidic acid
A recent study showed that lysophosphatidic acid (LPA) functioned as a pruritogen in the sera of patients with cholestatic liver disease. 146 LPA is a phospholipid derivative synthesized by the enzyme autotaxin, and acts as a signalling molecule. In addition, the study found that the activity of autotaxin in patients' sera correlated with the presence and intensity of pruritus. LPA and autotaxin may therefore be potential targets in the treatment of cholestatic pruritus.
Cerebral processes
There is increasing evidence to support the phenomenon of central sensitization in chronic pruritus, a process analogous to central sensitization in chronic pain. 147, 148 This process is thought to occur in the spinal cord in both instances. The latter has been attributed to a defective descending pain-inhibitory system arising from various areas in the brainstem, 149 and the cortical connections of these regions are unknown.
From the management point of view, treatment of pruritus should be instituted early to avoid development of central sensitization.
Little is known about the supraspinal processing of itch, and it is only in recent years that positron emission tomography and functional magnetic resonance imaging have been used to study the brains of healthy subjects and patients with AD. Induction of itch was found to activate various areas of the brain that are involved in sensory, motor and emotional functions, and these areas include the somatosensory areas I and II, supramarginal gyrus, inferior parietal lobe, anterior and posterior cingulate cortex, precuneus, and insula-claustrum complex. The areas of brain activation occurring in itch are similar to those of pain, except for the precuneus, which is involved in episodic memory retrieval and may be associated with the affective components of itch. 150, 151 Among the areas activated in itch, the cingulate cortex appears to be an important region involved in the processing of pruritus. Compared with controls, the cingulate cortex was found to be significantly activated in patients with AD after histamine was administered, and the degree of activation correlated with disease severity. 150 The cingulate cortex was also found to be deactivated after scratching in healthy subjects. 152 In addition to somatosensory input, the perception and interpretation of pruritus are very much influenced by cognitive and affective processes. Antidepressants [selective serotonin reuptake inhibitors (SSRIs) and mirtazapine] and gamma-aminobutyric acid (GABA)-ergic drugs (namely gabapentin and pregabalin) have been found to be effective in treating itch; their mechanisms of actions are unknown but they may work by modulating itch perception. Serotonin and GABA were found to inhibit the cingulate cortex in mice, 153 and activity in the cingulate cortex may be a mechanism by which these serotonergic and GABA-ergic drugs exert their effects. The anterior cingulate cortex is known to be involved in emotional and cognitive functions (such as reward anticipation), 154 and with the recent findings of its role in pruritus, it appears to be an important target in the development of centrally active antipruritic agents. Mirtazapine is a noradrenergic and specific serotonergic antidepressant that has been used to treat nocturnal itch 155 and malignancy-associated pruritus. 156, 157 Esmirtazapine (ORG-50,081), the (S)-(+)-enantiomer of mirtazapine, has a shorter half-life and is currently under development for the treatment of insomnia. 158, 159 Esmirtazapine would be a promising alternative for patients who benefit from mirtazapine but experience prolonged drowsiness following its use. Serotonin-noradrenaline reuptake inhibitors (SNRIs) are a class of antidepressants which has been used in the treatment of anxiety disorders, chronic neuropathic pain and fibromyalgia. 160 Among them, venlafaxine, desvenlafaxine (the synthetic active metabolite of venlafaxine), duloxetine and bicifadine have been used to treat neuropathic pain, while duloxetine, milnacipran and levomilnacipran (levo-isomer of milnacipran) have been used to treat fibromyalgia. The efficacy of SNRIs in itch has not been assessed, but they may potentially be useful in neuropathic itch and chronic itch associated with depression and ⁄or anxiety. In addition to the SSRIs, mirtazapine, and the SNRIs, NKR-1 antagonists may also possess concurrent antidepressive, anxiolytic and antipruritic properties. Vestipitant is under clinical evaluation as an anxiolytic and a potential antidepressant, 161, 162 and L-733,060 has been shown in animal studies to have antidepressive 163, 164 and anxiolytic 165 effects. Aprepitant, however, was found in clinical trials to be ineffective for major depressive disorder 166 and plans to market it as an antidepressant have since been abandoned. The efficacy of NKR-1 antagonists in pruritus through antagonism of substance P activity and modulation of emotions awaits further elucidation.
Brain imaging has enabled identification of the various cerebral areas activated by itch. It should be noted, however, that the central mechanisms in different types of itch may differ. An example is seen in the use of gabapentin -it was shown to be efficacious in haemodialysis-associated pruritus 167, 168 but caused worsening of pruritus of cholestasis. 169 Treatment of pruritus should therefore be tailored to target the different pathological mechanisms in various diseases and also individualized according to the medical comorbidities and requirements of each patient.
From the clinical point of view, management of chronic pruritus must address not only the skin pathology, but also peripheral neuropathy (if present), central sensitization, and the cognito-affective aspects. Targeting the brain is also of particular relevance in skin diseases in which there are many different types of mediators and triggers involved in causing itch, such as AD. Attempts to inhibit multiple peripheral receptors and mediators with multiple agents will conceivably incur many unwanted side-effects, and mediating the cerebral processing of itch may be a more fruitful approach. Besides pharmacotherapy, psychotherapy can be used in management of the affective dimension, and the approaches include psychoanalysis, psychodynamic therapy, guided affective imagery 170 and hypnosis. 171, 172 Management of the cognitive processes includes providing education, support and cognitive-behavioural therapy.
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Conclusion
With a better understanding of the pathological mechanisms of itch processing, targeting specific mediators and neuronal pathways offers a promising approach to more effective management of pruritus. In particular, the PAR-2 and H4 histamine receptor pathways, the opioid system, IL-31 and TRPV1 serve as targets for the development of novel antipruritic therapies. Clinically, management of pruritus should be instituted early and address the skin pathology, peripheral neuropathy, central sensitization and the cognito-affective aspects of the disease.
What's already known about this topic?
• Research interest in pruritus has spurred a tremendous increase in knowledge over the last few years.
• Management options for pruritus, however, are still limited and treatment is suboptimal.
What does this study add?
• Provides a review of the current knowledge and new discoveries regarding the pathogenesis of pruritus.
• Introduces promising drugs and identifies potential targets for the development of novel antipruritic therapies.
